Jenburkt Pharmaceuticals Limited (BOM:524731)

India flag India · Delayed Price · Currency is INR
1,025.50
-35.80 (-3.37%)
At close: Jan 23, 2026
-13.45%
Market Cap4.53B
Revenue (ttm)1.59B
Net Income (ttm)329.99M
Shares Out4.41M
EPS (ttm)74.77
PE Ratio13.72
Forward PEn/a
Dividend18.00 (1.70%)
Ex-Dividend DateJul 11, 2025
Volume1,975
Average Volume817
Open1,062.60
Previous Close1,061.30
Day's Range1,010.00 - 1,070.00
52-Week Range936.70 - 1,410.00
Beta0.38
RSI41.89
Earnings DateFeb 3, 2026

About Jenburkt Pharmaceuticals

Jenburkt Pharmaceuticals Limited researches and develops, manufactures, and markets pharmaceutical and healthcare products in India. The company offers products in various therapeutic areas, such as pain management, analgesic and anti-pyretics, muscle relaxants, nutraceuticals, neuropathic pain, anti-arthritic, anti-infectives, antifungals, antiulcerants/antacids, aphrodisiacs, antimalarials, anthelmintics, cough and cold, and anti- diabetics, as well as consumer products. It offers its products under the Allerzine, CartiSafe Forte, Eberjen, EC... [Read more]

Industry Pharmaceutical Preparations
Founded 1985
Employees 779
Stock Exchange Bombay Stock Exchange
Ticker Symbol 524731
Full Company Profile

Financial Performance

In 2024, Jenburkt Pharmaceuticals's revenue was 1.52 billion, an increase of 6.85% compared to the previous year's 1.42 billion. Earnings were 320.61 million, an increase of 23.42%.

Financial Statements